BMB-105

BMB-105
Clinical data
Other names	BMB105
Routes of; administration	Oral
Drug class	Serotonin 5-HT2C receptor agonist
ATC code	None;

Chemical compound

Pharmaceutical compound

BMB-105 is a selective serotonin 5-HT_2C receptor agonist of the phenylcyclopropylmethylamine (PCPMA) family which is under development for the treatment of excessive appetite and other symptoms in Prader–Willi syndrome.^[2]^[3] It is taken orally.

The drug is described as a highly selective biased agonist of the serotonin 5-HT_2C receptor, with activation of the G_q signaling pathway but minimal β-arrestin recruitment.

BMB-105 is under development by Bright Minds Biosciences.^[2]^[3] As of November 2025, it is in phase 1 clinical trials.^[3] The drug is described as a follow-on drug to Bright Mind Bioscience's more advanced candidate BMB-101 and as a potential "best-in-class" medication.^[3]

The exact chemical structure of BMB-105 does not yet appear to have been disclosed. However, it is known to be a 2-phenylcyclopropylmethylamine (PCPMA) derivative similarly to BMB-101 and to share structural commonalities with tranylcypromine.

References

1 2 "Delving into the Latest Updates on BMB-105 with Synapse". Synapse. 24 January 2026. Retrieved 27 March 2026.
1 2 3 4 Bryson S (13 November 2025). "Can BMB-105 ease insatiable hunger in PWS? Program to find out". Prader-Willi Syndrome News. Retrieved 27 March 2026.

Clinical data
Other names	BMB105
Routes of administration	Oral
Drug class	Serotonin 5-HT_2C receptor agonist
ATC code	None